Tezua sells Ness

The Tezua Fund is a publicly traded company which currently invests in nine hi-tech firms. Bioness was founded in 2004 by Mann to market NESS products in North America.

By YONI TEITZ
June 18, 2007 07:50

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The Tezua Fund announced Sunday that that it has signed an agreement to sell NESS, a medical equipment producer from Ra'anana, to Alfred Mann and American firm Bioness Inc. for a total of $75 million, including $28m. for NESS and the remainder in Bioness shares. The Tezua Fund is a publicly traded company which currently invests in nine hi-tech firms. Bioness was founded in 2004 by Mann to market NESS products in North America. NESS develops advanced bionic technology that uses electrical stimulation to rehabilitate muscle in paralyzed patients.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS